Imperva (NYSE: IMPV) negatively preannounced F2Q16 with lower than expected revenue and a wider loss than anticipated. Needham analyst, Scott ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE